Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the ACE Inhibitors Market Size Changed, over the years?

The market size for ACE inhibitors has been experiencing a consistent escalation in recent years. It is projected to expand from $7.15 billion in 2024 to $7.48 billion in 2025, recording a compound annual growth rate (CAGR) of 4.6%. This growth during the historic period is linked to several factors such as rising incidences of cardiovascular diseases, an increasing elderly population, clinical efficacy and safety standards, prevalence of diabetes, as well as endorsements and guidelines from regulatory authorities.

How Much Will the ACE Inhibitors Market Be Worth in 2029?

In the forthcoming years, the ACE inhibitors market is projected to experience robust growth, reaching $9.6 billion by 2029 with a compound annual growth rate (CAGR) of 6.4%. Factors contributing to this growth through the prediction period include the increasing worldwide prevalence of cardiovascular diseases, wider guidelines for hypertension treatment, enhancements in combination therapies, emphasis on managing heart failure, and improved healthcare access and awareness. Key trends anticipated during this period include a focus on protecting the kidneys, a preference for inhibitors of the renin-angiotensin system, generic competition and pricing pressures, patient-oriented healthcare practices, and regulatory changes and safety considerations.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10671&type=smp

Which is the Largest Company in the ACE Inhibitors Market?

Major companies operating in the ACE inhibitors market include Pfizer Inc., Novartis AG, Johnson & Johnson Private Limited, Merck KGaA, Sanofi S.A., Bayer AG, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Co., Takeda Pharmaceuticals Company, Daiichi Sankyo Company Ltd., UCB Schwarz Pharma Inc., Endo International plc, Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim, Bausch Health Companies Inc., Dr. Reddy’s Laboratories, Abbott Laboratories, Eli Lilly and Company, Cipla Limited, GlaxoSmithKline plc, Cadila Healthcare Limited, AbbVie Inc., Sandoz Group AG, Accord Healthcare Ltd., AstraZeneca plc, Lupin Limited, Macleods Pharmaceuticals Limited, Zydus lifescience Ltd., Apotex Inc.

What Are the Main Market Drivers in the ACE Inhibitors Industry?

The spike in hypertension conditions is anticipated to fuel the expansion of the ACE inhibitors market. Hypertension, medically referred to as high blood pressure, is typified by heightened pressure within the blood vessels. Medicines known as ACE inhibitors, or angiotensin-converting enzyme inhibitors, are employed in managing and controlling this condition. These drugs work by easing the blood vessels, hence lowering blood pressure and enhancing blood circulation. As indicated by the World Health Organization, a Switzerland-based specialized agency of the United Nations, in March 2023, hypertension affected around 1.28 billion adults aged 30-79 globally, with most (two-thirds) living in low- and middle-income countries. Over the past three decades, the number of people in this age bracket suffering from hypertension has surged by 650 million. Interestingly, about 46% of adults suffering from hypertension are oblivious of their condition as they are yet to receive a diagnosis. Thus, the mounting incidence of hypertension-related disorders is triggering the ascent of the ACE inhibitors market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10671&type=smp

How Is the ACE Inhibitors Market Segments Structured?

The ACE inhibitors market covered in this report is segmented –

1) By Type: Sulfhydryl-containing Agents, Dicarboxylate-containing Agents, Phosphonate-containing Agents

2) By Drug: Ramipril, Enalapril, Benazepril, Fosinopril, Captopril, Moexipril, Other Drugs

3) By Dosage Form: Oral Tablets, Oral Solutions

4) By Application: Heart Failure, Chronic Kidney Disease, Hypertension, Diabetes, Heart Attack, Other Applications

5) By End-Users: Hospitals, Online Drug Stores, Other End-Users

Subsegments:

1) By Sulfhydryl-Containing Agents: Captopril, Zofenopril

2) By Dicarboxylate-Containing Agents: Enalapril, Lisinopril, Ramipril, Quinapril, Benazepril, Perindopril

3) By Phosphonate-Containing Agents: Fosinopril

What Strategic Trends Are Transforming the ACE Inhibitors Market?

A notable trend gaining traction in the ACE inhibitors market is the emphasis on product innovations. Leading businesses in this industry are concentrating on developing unique products to consolidate their market position and achieve a competitive edge. For example, Travere Therapeutics, a US-based biopharmaceutical company, received FDA approval in February 2023 for FILSPARI (sparsentan), a ground-breaking non-immunosuppressive treatment to be used in patients diagnosed with IgA nephropathy (IgAN). The treatment regimen includes systemic glucocorticoids, angiotensin-converting enzyme (ACE) inhibitors, and antihypertensive medications, such as angiotensin-receptor blockers (ARBs). It stands out for being the only approved non-immunosuppressive therapy that can be taken orally once daily, aimed at treating adults with primary IgAN who are prone to quick disease progression and generally exhibit a UPCR of less than 1.5 g/g and proteinuria.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/ace-inhibitors-global-market-report

Which Global Regions Offer the Highest Growth in the ACE Inhibitors Market?

North America was the largest region in the ACE inhibitors market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global ACE inhibitors market report during the forecast period. The regions covered in the ace inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10671

This Report Delivers Insight On:

1. How big is the ace inhibitors market, and how is it changing globally?

2. Who are the major companies in the ace inhibitors market, and how are they performing?

3. What are the key opportunities and risks in the ace inhibitors market right now?

4. Which products or customer segments are growing the most in the ace inhibitors market?

5. What factors are helping or slowing down the growth of the ace inhibitors market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model